TWILIGHT-HF Subgroup Analysis Score
Patient characteristics
Select or enter the characteristics that apply.
The count is not a validated risk prediction. It must not be used to estimate an individual's bleeding risk, ischemic risk, or treatment benefit.
These are published overall-trial rates, shown as context only. They are not adjusted according to this point count.
Published TWILIGHT estimates at 12 months after randomization among selected patients who completed 3 months of ticagrelor plus aspirin without a major ischemic or bleeding event. These group-level trial estimates are not individual predictions.
About this exploratory tool
This page adds one point for each of six selected characteristics: age 65 years or older, female sex, ACS presentation, diabetes, CKD, and anemia. The simple count was constructed for educational illustration; it is not a score developed or validated by the TWILIGHT investigators.
Point-count rules
| Characteristic | Exploratory rule | Points |
|---|---|---|
| Age | ≥65 years | +1 |
| Sex | Female | +1 |
| Presentation | ACS | +1 |
| Diabetes | Present | +1 |
| CKD | eGFR <60 mL/min/1.73 m² | +1 |
| Anemia | Known / documented | +1 |
Count bands (arbitrary, not clinical risk strata)
| Count | Display band | Clinical meaning |
|---|---|---|
| 0–1 | Lower item count | No validated risk interpretation |
| 2–3 | Middle item count | No validated risk interpretation |
| 4–6 | Higher item count | No validated risk interpretation |
Clinical context
TWILIGHT randomized selected high-risk patients who had undergone PCI and completed 3 months of ticagrelor plus aspirin without a major ischemic or bleeding event. The trial compared continued ticagrelor with aspirin versus ticagrelor with placebo for the following 12 months. It did not establish the six-variable point count on this page as a prognostic score.
Evidence and references
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.